Drug Trial Radar · NCT04056325
Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
617
Actual
Start
Nov 27, 2019
Primary completion
Apr 30, 2021
Study completion Apr 30, 2021
Sponsor
- Lead sponsor
- Jennifer KeiserAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Public Health, Vientiane, Laos
- First posted
- Aug 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase 2, blinded and randomized clinical trial. The phase 2a trial is single blinded and conducted in Lao, while the phase 2b trial is double-blinded and conducted in Lao and Cambodia. The study aims at providing evidence on effective doses and safety of moxidectin in adults against infection with S. stercoralis in Laos (trial 2a) and efficacy and safety of moxidectin compared to ivermectin in adults against infection with S. stercoralis in Laos and Cambodia (trial 2b). The efficacy of the treatment will be assessed by collecting three stool samples once pre-treatment and once 21 days post-treatment. The stool samples will be analyzed by a quantitative Baermann assay.
Conditions
- Strongyloides Stercoralis Infection
Interventions
MoxidectinDrug
Monotherapy, oral administration, single dose, fixed dose
IvermectinDrug
Monotherapy, oral administration, single dose, weight dependent
Placebo oral tabletDrug
Monotherapy, oral administration, single dose, matching number of tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Observed Cure Rate Against Strongyloides StercoralisTime frame: Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institute of Public Health
Vientiane, Laos
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.